Regulation & Mechanism of Secretion of HCl in the Stomach

The Parietal Cell - The Source of HCl

Cellular Mechanism of HCl Secretion

The Proton Pump (H+/K+-ATPase)

• The H+/K+-ATPase is a heterodimer consisting of a catalytic α-subunit and a glycoprotein β-subunit, assembled in the endoplasmic reticulum.
• In the resting state, the pump is stored in intracellular tubulovesicles; no significant acid secretion occurs.
• Upon stimulation, cytoskeletal rearrangements drive translocation of tubulovesicles, which fuse with the apical secretory canaliculi, enlarging the secretory surface area 6-10 times. The H+/K+-ATPase is then inserted into the canalicular membrane.
• The pump performs electroneutral ion exchange: cytosolic H+ is actively pumped into the lumen in exchange for extracellular K+ (requires ATP since H+ is secreted against a massive gradient).
• Simultaneously, apical K+ and Cl- channels supply luminal K+ for exchange and Cl- for HCl formation.
• Basolateral bicarbonate-chloride exchangers export one HCO3- for every H+ secreted ("alkaline tide"), and import Cl- to replenish the apical Cl- supply.
• The net result: H+ + Cl- = HCl, secreted at pH ~0.8 (160 mM).
• Cessation of acid secretion involves endocytosis of H+/K+-ATPase back into tubulovesicles, triggered by a tyrosine-based signal on the cytoplasmic tail of the β-subunit.

Fig: Parietal cell intracellular signaling - Histamine (H2 → Gs → cAMP → PKA), ACh/Gastrin (M3/CCK-B → PLC → IP3 → Ca2+), and Somatostatin (Gi → ↓cAMP) all converge on H+/K+-ATPase. (Sabiston Textbook of Surgery)

Three Stimulatory Pathways to the Parietal Cell

Histamine is considered the most important stimulator because it acts via the H2 receptor as the final paracrine mediator. This is why H2-receptor antagonists and proton pump inhibitors (PPIs) are so effective clinically.

Regulatory Cell Types

Fig: The parietal cell and its relationships - G cells release gastrin → ECL cells release histamine → parietal cell H2 receptor → HCl. ACh acts via M3. (Bailey & Love's Surgery)

Phases of Gastric Acid Secretion (Physiological Regulation)

1. Cephalic Phase (~30% of meal-stimulated output)

• Triggered by the thought, sight, smell, and taste of food.
• Cortical/hypothalamic stimuli activate the vagal dorsal motor nucleus (DMN) and nucleus tractus solitarius (NTS).
• Efferent vagal fibers synapse with submucosal enteric neurons → release acetylcholine (ACh).
• ACh acts directly on parietal cells (M3) AND stimulates antral G cells (via GRP) to release gastrin.
• Vagal stimulation also sensitizes ECL cells to gastrin.
• Sham feeding (chewing and spitting) stimulates acid to ~50% of maximum - purely via this phase.

2. Gastric Phase (~60% of meal-stimulated output)

• Begins when food enters the stomach; lasts until the stomach empties.
• Mechanical component: Gastric distension activates vagovagal reflex arcs and local enteric reflexes → ACh release → parietal cell stimulation.
• Chemical component: Amino acids and small peptides directly stimulate antral G cells → gastrin release into blood → stimulates ECL cells (histamine) and parietal cells directly.
• The buffering effect of food (raising luminal pH) removes the tonic acid-inhibition of G cells, thus amplifying gastrin release.

3. Intestinal Phase (~10% or less of meal-stimulated output)

• As chyme enters the duodenum and small bowel.
• Initially mildly stimulatory (enterooxyntin from small intestinal mucosa).
• Rapidly becomes predominantly inhibitory once duodenal acidification occurs:
  • Acidification → secretin release → inhibits gastric acid secretion.
  • Additional enterogastrones (GIP, CCK, glucagon-like peptide-1) inhibit acid.
  • Hyperosmolar/fatty chyme also triggers inhibitory reflexes.

Inhibitory Regulation (Negative Feedback)

Summary Diagram

Vagus → ACh → M3 on parietal cell + G cell (via GRP) → Gastrin → CCK-2 on ECL cell → Histamine → H2 on parietal cell → cAMP → PKA → H+/K+-ATPase → HCl

Luminal acid → D cell → Somatostatin → SSTR2 on G cell + ECL cell + parietal cell → ↓Gastrin, ↓Histamine, ↓H+/K+-ATPase activity

Clinical Relevance

• PPIs (omeprazole, pantoprazole) - irreversibly bind the activated H+/K+-ATPase at the cysteine residues of the α-subunit; most effective when taken before meals when parietal cells are stimulated. Acid secretion recovers in days as new pump is synthesized.
• H2 blockers (famotidine) - block the H2 receptor; effective but limited since they block only one of three pathways; tachyphylaxis can occur due to CCK-2 receptor upregulation.
• Potassium-competitive acid blockers (PCABs) (vonoprazan) - bind ionically to H+/K+-ATPase, blocking K+ access; work even in the resting state unlike PPIs.
• Helicobacter pylori: antrum-predominant infection → ↑gastrin → hypersecretion; corpus-predominant infection → ↓acid (parietal cell mass lost).
• Zollinger-Ellison syndrome: gastrinoma → unregulated gastrin → massive acid hypersecretion → refractory peptic ulcers.

Peptic Ulcer Disease - Clinical Case Discussion

THE CASE

• 3-month history of burning epigastric pain, worse 2-4 hours after meals and at night, relieved by eating food or antacids
• History of taking diclofenac (NSAID) regularly for knee pain for 6 months
• Smokes 10 cigarettes/day; occasional alcohol
• No weight loss, no vomiting of blood, no black stools

• Mild epigastric tenderness on deep palpation
• No guarding or rigidity
• No palpable mass
• Vital signs: normal

STEP 1 - DIFFERENTIAL DIAGNOSIS

Working diagnosis: Peptic ulcer disease (likely duodenal) - NSAID-related +/- H. pylori

STEP 2 - PATHOPHYSIOLOGY (What's happening in this patient?)

Defensive Factors (reduced in PUD):

• Mucus-bicarbonate barrier (gel layer trapping HCO3-)
• Mucosal blood flow
• Prostaglandin E2 (maintains mucus/HCO3- secretion)
• Cell renewal and growth factors

Aggressive Factors (increased in PUD):

• HCl + pepsin
• H. pylori infection (present in ~90% of duodenal ulcers)
• NSAIDs - inhibit COX-1 → ↓prostaglandin synthesis → ↓mucus and HCO3- → mucosal injury; also direct topical injury
• Smoking (↓mucosal blood flow, ↓prostaglandins)
• Alcohol
• Stress (Curling's ulcer post-burn; Cushing's ulcer in CNS injury)

How H. pylori causes duodenal ulcer:

1. H. pylori (gram-negative, microaerophilic, flagellated spiral bacillus) colonizes the gastric antrum
2. Its urease enzyme converts urea → NH3 + HCO3-, creating an alkaline microenvironment allowing survival
3. Colonization → inhibits somatostatin secretion by antral D cells
4. ↓Somatostatin → removes tonic inhibition of G cells → ↑gastrin secretion
5. ↑Gastrin → ↑parietal cell HCl output → excess H+ delivered to duodenum
6. H. pylori also spreads to duodenum → inhibits duodenal HCO3- secretion
7. Net result: ↑acid load + ↓buffering → duodenal mucosal erosion

STEP 3 - GASTRIC vs. DUODENAL ULCER: KEY DIFFERENCES

Johnson Classification of Gastric Ulcer Types (surgical relevance):

STEP 4 - INVESTIGATIONS

For Diagnosis:

1. Upper GI Endoscopy (OGD) - gold standard
   • Confirms location, depth, appearance of ulcer
   • Biopsy of gastric ulcers: mandatory in all cases (4 quadrants - first biopsy alone has 70% sensitivity; 4 specimens = 95%; 7 specimens = 98%)
   • Duodenal ulcers: biopsy not routinely needed for malignancy (rarely malignant)
   • Can be therapeutic (bleeding control)
2. Barium meal (upper GI series) - largely replaced by endoscopy
   • Single contrast: misses 50% of ulcers; double contrast: detects 80-90%

For H. pylori:

Other labs:

• FBC (anemia in bleeding)
• Fasting serum gastrin (if ZES suspected - multiple/refractory ulcers, diarrhea, steatorrhea)
• LFTs, renal function

STEP 5 - TREATMENT

A. Lifestyle Modifications

• Stop NSAIDs/aspirin if possible
• Smoking cessation
• Avoid alcohol
• Small frequent meals (reduces acid peaks)

B. Pharmacological Treatment

• Omeprazole, pantoprazole, lansoprazole, rabeprazole, esomeprazole
• Mechanism: prodrug → activated in parietal cell canaliculus → covalent disulfide bond to cysteine on H+/K+-ATPase α-subunit → irreversible inhibition
• Healing rate: 85% at 4 weeks, 96% at 8 weeks
• Take before meals (parietal cell must be stimulated for drug activation)
• Maintenance PPI: for large ulcers (>2 cm), refractory disease, failed H. pylori eradication, or continued NSAID/aspirin requirement

• Famotidine, cimetidine, ranitidine (ranitidine withdrawn globally April 2020 - NDMA contamination risk)
• Second-line; may cause tachyphylaxis
• Do NOT combine with PPIs (H2RAs create alkaline environment, preventing PPI activation)

C. H. pylori Eradication (when H. pylori positive)

PPI + Clarithromycin + Amoxicillin (x 14 days)

PPI + Bismuth subcitrate + Tetracycline + Metronidazole (10-14 days)

PPI + Levofloxacin + Amoxicillin (10-14 days)

~20-30% of patients fail initial therapy (increasing antibiotic resistance). These need second-line regimens guided by susceptibility.

STEP 6 - COMPLICATIONS OF PUD (The "BOOP" of PUD)

Bleeding PUD - Emergency Management:

• ABC resuscitation - large-bore IV access, fluids, blood products
• IV PPI immediately on admission
• Prokinetic (IV erythromycin) before endoscopy to improve visualization
• Urgent endoscopy within 24 hours (diagnostic + therapeutic)
• Endoscopic hemostasis: hemostatic clips, electrocoagulation, argon plasma coagulation, injection (epinephrine NOT as monotherapy - combine with another modality)
• Post-endoscopy: IV PPI for 72 hours, then oral PPI ≥2 weeks
• Rebleed → repeat endoscopy → if fails: interventional radiology (transarterial embolization) → if fails: surgery

Forrest Classification (endoscopic risk stratification):

Forrest IA, IB, IIA require endoscopic intervention. IIB - controversial. IIC/III - no intervention needed.

Perforation - Emergency:

• Sudden severe "board-like" epigastric rigidity
• Upright CXR: free gas under diaphragm (pneumoperitoneum)
• CT abdomen confirms
• Initial: IV PPI, NBM, IV antibiotics, NG tube decompression
• Surgical: omental patch repair (Graham patch) + H. pylori eradication
• Mortality 30-50% in elderly/debilitated patients

STEP 7 - SPECIAL SITUATIONS

Zollinger-Ellison Syndrome (ZES / Gastrinoma)

• Gastrin-secreting tumor (usually pancreatic islet cell; 25% in MEN-1)
• Multiple, refractory, atypical ulcers (jejunal ulcers)
• Diarrhea and steatorrhea (low duodenal pH inactivates pancreatic lipases)
• Diagnosis: fasting serum gastrin >1000 pg/mL; secretin stimulation test
• Gastrin is NOT inhibited by H+ (unlike physiological G cells)
• Treatment: High-dose PPI + surgical resection of tumor

NSAID-related ulcers

• COX-1 inhibition → ↓prostaglandins → ↓mucus/HCO3- + ↓mucosal blood flow
• Prevention: use COX-2 selective NSAIDs (celecoxib) OR add misoprostol/PPI
• Type V Johnson classification
• Often painless (NSAIDs also suppress pain perception) → may present with occult bleeding

Stress Ulcers (in ICU)

• Curling's ulcer: major burns (ischemia of mucosa)
• Cushing's ulcer: CNS injury (vagal hyperactivity → ↑acid)
• Prophylaxis with PPI or sucralfate in ventilated/coagulopathic ICU patients

SUMMARY TABLE: Gastric vs. Duodenal Ulcer at a Glance